News

Embody Advances Biologic Augmentation Market with First-Of-Its-Kind Collagen Implant

Embody, Inc., a privately-held medical device company developing novel collagen-based technologies for soft tissue injury and repair, announced today the expansion and clinical use cases of TAPESTRY® Biointegrative Implant in the U.S. market. TAPESTRY Biointegrative Implant is the first collagen-based implant with a bioengineered micro-architecture and biostimulative, highly organized type I collagen chemistry specifically designed for the management and protection of tendon injuries. The unique combination of the collagen chemistry and structural integrity provides unparalleled clinical utility and sizing across a broad range of tendon applications including, but not limited to, foot and ankle, knee, and shoulder procedures.

“Catastrophic failure and clinical dysfunction associated with poor subscapularis tendon healing rates following shoulder arthroplasty leads to suboptimal functional outcomes and costly re-operations for our patients,” said Amit Nathani, MD, an Orthopaedic Surgeon and Shoulder Specialist in Santa Barbara, California. “TAPESTRY combines the benefits of collagen-based chemistry with unique sizing, hydrophilicity, and handling characteristics appropriate to augment total shoulder procedures, offering the potential to enhance healing and reduce soft tissue failures.”

“There is a strong clinical need for a better solution to treat tendon injury of the foot & ankle,” said Alan Ng, DPM, FACFAS, at Advanced Orthopedic & Sports Medicine Specialists in Denver, CO. “The TAPESTRY implant is unlike anything else I have used in its ability to form new, dense collagenous tissue at the site of the implantation combined with its superior handling and sizing make it ideal for a variety of challenging tendon procedures including Achilles and paroneal tendons.”

“Following the initial surgical procedures with TAPESTRY, we are seeing continued use and expanded interest across a wide range of demanding tendon applications including subscapularis, patellar, peroneal and Achilles tendons where formative products have lacked the combination of handling, structural integrity, and a biostimulative chemistry,” said Jeff Conroy, CEO of Embody. “We continue to expand our range of sizes and shapes to rapidly accommodate every surgeon’s need.”

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep